| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.02 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.03 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.03 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.03 |